Going both ways: Immune regulation via CD1d-dependent NKT cells

Journal of Clinical Investigation

Volumn 114, Issue 10, 2004, Pages 1379-1388

  Godfrey, Dale I ^a   Kronenberg, Mitchell ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA GALACTOSYLCERAMIDE DERIVATIVE; ANTIGEN; CD1D ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 4; PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CD1 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; AUTOIMMUNITY; CANCER; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL LINEAGE; CELL TYPE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; TUMOR REJECTION; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; COMPARATIVE STUDY; DISEASE MODEL; FORECASTING; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS; ANTIGENS, CD1; AUTOIMMUNITY; CELL LINEAGE; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FORECASTING; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATION; KILLER CELLS, NATURAL; MODELS, BIOLOGICAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; UP-REGULATION;

EID: 10044286529     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200423594     Document Type: Review

References (124)

1. Godfrey, D.I., MacDonald, H.R., Kronenberg, M., Smyth, M.J., and Van Kaer, L. 2004. NKT cells: what's in a name? Nat. Rev. Immunol. 4:231-237.
2. Godfrey, D.I., Hammond, K.J., Poulton, L.D., Smyth, M.J., and Baxter, A.G. 2000. NKT cells facts, functions and fallacies. Immunol. Today. 21:573-583.
3. Kronenberg, M., and Gapin, L. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2:557-568.
4. - T cells. J. Exp. Med. 180:1171-1176.
5. Porcelli, S., Yockey, C.E., Brenner, M.B., and Balk, S.P. 1993. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several Vbeta genes and an invariant TCR alpha chain. J. Exp. Med. 178:1-16.
6. Brossay, L., et al. 1998. Cd1d-mediated recognition of an alpha-galactosylceramide by natural killer t cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521-1528.
7. MacDonald, H.R. 2002. Development and selection of NKT cells. Curr. Opin. Immunol. 14:250-254.
8. Hammond, K.J.L., et al. 1999. NKT cells are phenotypically and functionally diverse. Eur. J. Immunol. 29:3768-3781.
9. Matsuda, J.L., et al. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-754.
10. Eberl, G., et al. 1999. Tissue-specific segregation of CD1d-dependentand CD1d-independent NK T cells. J. Immunol. 162:6410-6419.
11. + T cells preferentially accumulate in human liver. Eur. J. Immunol. 29:2406-2413.
12. Gumperz, J.E., Miyake, S., Yamamura, T., and Brenner, M.B. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195:625-636.
13. Prussin, C., and Foster, B. 1997. TCR V-alpha-24 and V-beta-11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation. J. Immunol. 159:5862-5870.
14. Exley, M.A., et al. 2002. Cutting edge: compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J. Immunol. 168:1519-1523.
15. Kenna, T., et al. 2003. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171:1775-1779.
16. Gumperz, J.E., and Brenner, M.B. 2001. CD1-specific T cells in microbial immunity [review]. Curr. Opin. Immunol. 13:471-478.
17. Hayakawa, Y., Godfrey, D.I., and Smyth, M.J. 2004. Alpha- galactosylceramide: potential immunomodulatory activity and future application. Curr. Med. Chem. 11:241-252.
18. Hong, S.M., et al. 1999. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol. Rev. 169:31-44.
19. Sidobre, S., et al. 2002. The V alpha 14 NKT cell TCRexhibits high-affinity binding to a glycolipid/ CD1d complex. J. Immunol. 169:1340-1348.
20. Hammond, K.J., et al. 2001. CD1d-restricted NKT cells: an incerstrain comparison. J. Immunol. 167:1164-1173.
21. Benlagha, K., Weiss, A., Beavis, A., Teyton, L., and Bendelac, A. 2000. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191:1895-1903.
22. Wu, D.Y., Segal, N.H., Sidobre, S., Kronenberg, M., and Chapman, P.B. 2003. Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells. J. Exp. Med. 198:173-181.
23. Hansen, D.S., Siomos, M.A., Buckingham, L., Scaho, A.A., and Schofield, L. 2003. Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. Immunity. 18:391-402.
24. Schofield, L., et al. 1999. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science. 283:225-229.
25. Rauch, J., et al. 2003. Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J. Biol. Chem. 278:47508-47515.
26. Ortaldo, J.R., et al. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172:943-953.
27. Smyth, M.J., and Godfrey, D.I. 2000. NKT cells and tumor immunity-a double-edged sword. Nat. Immunol. 1:459-460.
28. Wilson, S.B., and Delovitch, T.L. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3:211-222.
29. Matsuda, J.L., et al. 2003. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:8395-8400.
30. Stetson, D.B., et al. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med. 198:1069-1076.
31. Crowe, N.Y., et al. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol. 171:4020-4027.
32. Lee, P.T., Benlagha, K., Teyton, L., and Bendelac, A. 2002. Distinct functional lineages of human V alpha-24 natural killer T cells. J. Exp. Med. 195:637-641.
33. Wang, Y., Goldschneider, I., O'Rourke, J., and Cone, R.E. 2001. Blood mononuclear cells induce regulatory NK T thymocytes in anterior chamber-associated immune deviation. J. Leukoc. Biol. 69:741-746.
34. Wang, Y.F., et al. 1997. Direct thymic involvement in anterior chamber-associated immune deviation - evidence for a nondeletional mechanism of centrally induced tolerance to extrathymic antigens in adult mice J. Immunol. 158:2150-2155.
35. Sonoda, K.H., Exley, M., Snapper, S., Balk, S.P., and Stein-Streilein, J. 1999. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190:1215-1225.
36. Sonoda, K.H., et al. 2001. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J. Immunol. 166:42-50.
37. Nakamura, T., et al. 2003. CD4(+) NKT cells, but not conventional CD4(+) T cells, are required to generate efferent CD8(+) T regulatory cells following antigen inoculation in an immune-privileged site J. Immunol. 171:1266-1271.
38. Nishikawa, H., et al. 2003. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. U. S. A. 100:10902-10906.
39. Azuma, T., Takahashi, T., Kunisato, A., Kitamura, T., and Hirai, H. 2003. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 63:4516-4520.
40. Sonoda, K.H., Taniguchi, M., and Stein-Streilein, J. 2002. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J. Immunol. 168:2028-2034.
41. Seino, K.-I., et al. 2001. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. U. S. A. 98:2577-2581.
42. Higuchi, M., et al. 2002. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J. Immunol. 169:5564-5570.
43. + Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J. Clin. Invest. 105:1761-1767.
44. + T cells reciprocally regulate acute graft versus host disease. J. Exp. Med. 189:1073-1081.
45. Lan, F., et al. 2001. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J. Immunol. 167:2087-2096.
46. Ito, K., et al. 2000. Involvement of decidual V alpha 14 NKT cells in abortion. Proc. Natl. Acad. Sci. U. S. A. 97:740-744.
47. Hammond, K.J., and Godfrey, D.I. 2002. NKT cells: potential targets for autoimmune disease therapy? Tissue Antigens. 59:353-363.
48. Hammond, K.J., and Kronenberg, M. 2003. Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr. Opin. Immunol. 15:683-689.
49. - T cell deficiency and IDDM in NOD/Lt mice. Diabetes. 46:572-582.
50. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD/Lt) mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187:1047-1056.
51. Lehuen, A., et al. 1998. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188:1831-1839.
52. Poulton, L.D., et al. 2001. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int. Immunol. 13:887-896.
53. Hong, S., et al. 2001. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7:1052-1056.
54. --like thymocytes in the NOD mouse. Eur. J. Immunol. 26:2989-2998.
55. Wang, B., Geng, Y.B., and Wang, C.R. 2001. CD1-restricted NKT cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194:313-320.
56. Sharif, S., et al. 2001. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7:1057-1062.
57. Naumov, Y.N., et al. 2001. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. U. S. A. 98:13838-13843.
58. Beaudoin, L., Laloux, V., Novak, J., Lucas, B., and Lehuen, A. 2002. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity. 17:725-736.
59. Wilson, S.B., et al. 1998. Extreme TH1 bias of invariant V-alpha-24J-alpha-Q T cells in type 1 diabetes. Nature. 391:177-181.
60. Kukreja, A., et al. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Infest. 109:131-140. doi:10.1172/JCI200213605.
61. Oikawa, Y., et al. 2002. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care. 25:1818-1823.
62. Lee, P.T., et al. 2002. Testing the NKT cell hypothesis of human IDDM pathogenesis. J. Clin. Invest. 110:793-800. doi:10.1172/JCI200215832.
63. Berzins, S.P., et al. 2004. Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies. Immunol. Cell Biol. 82:247-252.
64. Furlan, R., et al. 2003. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 33:1830-1838.
65. Jahng, A.W., et al. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1789-1799.
66. Singh, A.K., et al. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1801-1811.
67. Pal, E., et al. 2001. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J. Immunol. 166:662-668.
68. Miyamoto, K., Miyake, S., and Yamamura, T. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:531-534.
69. Chiba, A., et al. 2004. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 50:305-313.
70. Stanic, A.K., et al. 2003. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural TCR. J. Immunol. 171:4539-4551.
71. Hayakawa, Y., et al. 2001. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metascatic effect of alpha-galactosylceramide. Eur. J. Immunol. 31:1720-1727.
72. Carnaud, C., et al. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:4647-4650.
73. Mars, L.T., et al. 2002. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 168:6007-6011.
74. Araki, M., et al. 2003. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int. Immunol. 15:279-288.
75. Takeda, K., and Dennert, G. 1993. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type-1 positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J. Exp. Med. 177:155-164.
76. + NKT cells associated with disease development in autoimmune-prone mice. J. Immunol. 156:4035-4040.
77. Yang, J.Q., et al. 2003. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J. Immunol. 171:2142-2153.
78. Yang, J.Q., et al. 2004. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur. J. Immunol. 34:1723-1732.
79. Chan, O.T., et al. 2001. Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: an example of disease regulation at the organ level. J. Immunol. 167:2985-2990.
80. Yang, J.Q., et al. 2003. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J. Immunol. 171:4439-4446.
81. Zeng, D., Liu, Y., Sidobre, S., Kronenberg, M., and Strober, S. 2003. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 112:1211-1222. doi:10.1172/JCI200317165.
82. Zeng, D., Lee, M.K., Tung, J., Brendolan, A., and Strober, S. 2000. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J. Immunol. 164:5000-5004.
83. Saubermann, L.J., et al. 2000. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology. 119:119-128.
84. Heller, F., Fuss, I.J., Nieuwenhuis, E.E., Blumberg, R.S., and Strober, W. 2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 17:629-638.
85. van der Vliet, H.J., et al. 2001. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100:144-148.
86. Kita, H., et al. 2002. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology. 123:1031-1043.
87. Smyth, M.J., Crowe, N.Y., Takeda, K., Yagita, H., and Godfrey, D.I. 2002. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 14:165-171.
88. Cui, J., et al. 1997. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 278:1623-1626.
89. Kawano, T., et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science. 278:1626-1629.
90. Hayakawa, Y., Rovero, S., Forni, G., and Smyth, M.J. 2003. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 100:9464-9469.
91. Smyth, M.J., et al. 2002. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 99:1259-1266.
92. Schmieg, J., Yang, G., Franck, R.W., and Tsuji, M. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J. Exp. Med. 198:1631-1641.
93. Kitamura, H., et al. 1999. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopocentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121-1127.
94. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., and Steinman, R.M. 2003. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-279.
95. Smyth, M.J., et al. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661-668.
96. Crowe, N.Y., Smyth, M.J., and Godfrey, D.I. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-127.
97. Terabe, M., et al. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-520.
98. Ostrand-Rosenberg, S., et al. 2002. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J. Immunol. 169:5796-5804.
99. Terabe, M., et al. 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741-1752.
100. Moodycliffe, A.M., Nghiem, D., Clydesdale, G., and Ullrich, S.E. 2000. Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol. 1:521-525.
101. Motohashi, S., et al. 2002. Preserved IFN-alpha production of circulating V alpha 24 NKT cells in primary lung cancer patients. Int. J. Cancer. 102:159-165.
102. Ali Tahir, S.M., et al. 2001. Loss of IFN-gamma production by invariant NKT cells in advanced cancer. J. Immunol. 167:4046-4050.
103. Dhodapkar, M.V., et al. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197:1667-1676.
104. Kawano, T., et al. 1999. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 59:5102-5105.
105. Kikuchi, A., et al. 2001. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br. J. Cancer. 85:741-746.
106. Metelitsa, L.S., et al. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167:3114-3122.
107. Giaccone, G., et al. 2002. A phase I study of the natural killer T-cell ligand alpha-Galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8:3702-3709.
108. Nieda, M., et al. 2004. Therapeutic activation of V{alpha}24+V{beta}11 + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 103:383-389.
109. Fujii, S., Shimizu, K., Kronenberg, M., and Steinman, R.M. 2002. Prolonged IFN-gamma-producing NKT response induced with alpha- galactosylceramide-loaded DCs. Nat. Immunol. 3:867-874.
110. Johnson, T.R., Hong, S.M., Van Kaer, L., Koezuka, Y., and Graham, B.S. 2002. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J. Virol. 76:4294-4303.
111. Levy, O., et al. 2003. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J. Infect. Dis. 188:948-953.
112. Grubor-Bauk, B., Simmons, A., Mayrhofer, G., and Speck, P.G. 2003. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J. Immunol. 170:1430-1434.
113. Roberts, T.J., Lin, Y., Spence, P.M., Van Kaer, L., and Brutkiewicz, R.R. 2004. CD1d1-dependent control of the magnitude of an acute antiviral immune response. J. Immunol. 172:3454-3461.
114. Brigl, M., Bry, L., Kent, S.C., Gumperz, J.E., and Brenner, M.B. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230-1237.
115. Apostolou, I., et al. 1999. Murine natural killer T (NKT) cells contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc. Natl. Acad. Sci. U. S. A. 96:5141 -5146.
116. Mempel, M., et al. 2002. Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells. J. Immunol. 168:365-371.
117. Fischer, K., et al. 2004. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl. Acad. Sci. U. S. A. 101:10685-10690.
118. Korsgren, M., et al. 1999. Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J. Exp. Med. 189:553-562.
119. Lisbonne, M., et al. 2003. Cutting edge: invariant Valpha14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. 171:1637-1641.
120. Akbari, O., et al. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9:582-588.
121. Bilenki, L., Yang, J., Fan, Y., Wang, S., and Yang, X. 2004. Natural killer T cells contribute to airway eosinophilic inflammation induced by ragweed through enhanced IL-4 and eotaxin production. Eur. J. Immunol. 34:345-354.
122. Prell, C., et al. 2003. Frequency of Valpha24+CD161+ natural killer T cells and invariant TCRAV24-AJ18 transcripts in atopic and non-atopic individuals. Immunobiology. 208:367-380.
123. Campos, R.A., et al. 2003. Cutaneous immunization rapidly activates liver invariant Valpha14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J. Exp. Med. 198:1785-1796.
124. Tupin, E., et al. 2004. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199:417-422.